A Scalable Model
Defence Therapeutics has developed two strategic pathways to market. Each is 100% owned and holds individual IP value, while also working in combination with the other for overall increased value:
Technology
100% Owned
Read More
- Primary asset: Clinical research, ADC Platform, ACCUM™ Technology
- Proprietary platform technology with proven enhanced drug delivery method
- Applications in oncology, vaccine development, and nanotechnologies
- Full ownership of assets and IP
- Pharma & biotech company collaborations
- Supported by Jeff Leyton, Ph.D
Vaccine Development
100% Owned
Read More
- ACCUM™ enhanced infectious disease + virus vaccines
- Priority COVID-19 vaccine
- Priority Cancer vaccines
- Full ownership of assets and IP
- Research contract in process with University of Montreal
- Supported by Moutih Rafei, Ph.D
Learn more about our Accum™ Technology & Vaccine development: